1. Pink Sheet
  3. >>Clinical Trials

GSK Leads Way With Real World Data, But Others Follow

 
• By Emily Hayes

The firm's hands-off pragmatic trial in the UK paves the way for real world studies in other disease areas where there are many products and arguably little differentiation to sway payers on market access.

Increasingly, health care providers and payers want to see studies reflective of real world situations and proof that health care is being delivered in the most cost-effective way, which was part of the aim of GlaxoSmithKline PLC's Salford Lung Study.

The 2,802-patient study compared GSK's Breo Ellipta, which combines the inhaled corticosteroid fluticasone furoate with the long-acting beta agonist vilanterol, against physician's choice, to reflect an everyday clinical practice setting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

EMA Official Clarifies Benefits And Limitations Of Innovation Pathways

 
• By Eliza Slawther

A European Medicines Agency official provided an overview and update of the support the EMA offers developers of innovative products and discussed, among other things, its Innovation Task Force, Quality Innovation Group and a scientific advice pilot for clinical trials.

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 
• By Eliza Slawther

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.